Biora Therapeutics, Inc.

OTCPK:BIOR.Q 주식 리포트

시가총액: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics 경영진

경영진 기준 점검 3/4

Biora Therapeutics CEO는 Adi Mohanty, Nov2021 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $3.14M, 18.3% 급여 및 81.7% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.10K 가치에 해당하는 회사 주식의 0.52% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.3 년과 3.9 년입니다.

핵심 정보

Adi Mohanty

최고경영자

US$3.1m

총 보수

CEO 급여 비율18.29%
CEO 재임 기간3.5yrs
CEO 지분 보유율0.5%
경영진 평균 재임 기간3.3yrs
이사회 평균 재임 기간3.9yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

CEO 보수 분석

Adi Mohanty의 보수는 Biora Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$3mUS$574k

-US$124m

Sep 30 2023n/an/a

-US$122m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$4mUS$550k

-US$49m

Sep 30 2022n/an/a

-US$118m

Jun 30 2022n/an/a

-US$140m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$10mUS$63k

-US$179m

보상 대 시장: Adi의 총 보수(USD3.14M)는 US 시장에서 비슷한 규모 기업의 평균(USD659.85K)보다 높습니다.

보상과 수익: Adi의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Adi Mohanty (57 yo)

3.5yrs
재임 기간
US$3,139,017
보수

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

리더십 팀

이름직위재임 기간보수지분
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Clarke Neumann
Senior VP10.7yrsUS$1.53m0.18%
$ 1.1k
Kevin Howe
Senior VP of Strategic Operationsno data데이터 없음데이터 없음
Paul Shabram
Head of Technical Operations3.1yrs데이터 없음데이터 없음
James Knight
Head of Business Development1.3yrs데이터 없음데이터 없음
3.3yrs
평균 재임 기간

경험이 풍부한 관리: BIOR.Q의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.3 년).

이사회 구성원

이름직위재임 기간보수지분
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Brian Gordon Feagan
Member of Inflammatory Bowel Disease Clinical Advisory Boardno data데이터 없음데이터 없음
Brian Kotzin
Independent Director5.9yrsUS$185.11k0.041%
$ 245.8
Geert D'Haens
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrs데이터 없음데이터 없음
Bruce Sands
Chairman of Inflammatory Bowel Disease Clinical Advisory Board3.9yrs데이터 없음데이터 없음
Jeffrey Alter
Independent Chairman6.3yrsUS$208.11k0.043%
$ 256.5
Lynne Powell
Independent Director6.3yrsUS$163.11k0.041%
$ 245.7
Severine Vermeire
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrs데이터 없음데이터 없음
Jill Howe
Independent Director3.5yrsUS$180.11k0.040%
$ 241.1
3.9yrs
평균 재임 기간
57yo
평균 나이

경험이 풍부한 이사회: BIOR.Q의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.9 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2025/05/27 03:29
종가2025/05/27 00:00
수익2024/09/30
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Biora Therapeutics, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates